Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

G. M. Marshall, S. Gherardi, N. Xu, Z. Neiron, T. Trahair, C. J. Scarlett, D. K. Chang, P. Y. Liu, K. Jankowski, N. Iraci, M. Haber, M. D. Norris, J. Keating, E. Sekyere, G. Jonquieres, F. Stossi, Benita S Katzenellenbogen, A. V. Biankin, G. Perini, T. Liu

Research output: Contribution to journalArticle

Abstract

Myc oncoproteins and histone deacetylases (HDACs) modulate gene transcription and enhance cancer cell proliferation, and HDAC inhibitors are among the most promising new classes of anticancer drugs. Here, we show that N-Myc and c-Myc upregulated HDAC2 gene expression in neuroblastoma and pancreatic cancer cells, respectively, which contributed to N-Myc-and c-Myc-induced cell proliferation. Cyclin G2 (CCNG2) was commonly repressed by N-Myc and HDAC2 in neuroblastoma cells and by c-Myc and HDAC2 in pancreatic cancer cells, and could be reactivated by HDAC inhibitors. 5-bromo-2′- deoxyuridine incorporation assays showed that transcriptional repression of CCNG2 was, in part, responsible for N-Myc-, c-Myc-and HDAC2-induced cell proliferation. Dual crosslinking chromatin immunoprecipitation assay demonstrated that N-Myc acted as a transrepressor by recruiting the HDAC2 protein to Sp1-binding sites at the CCNG2 gene core promoter. Moreover, HDAC2 was upregulated, and CCNG2 downregulated, in pre-cancerous and neuroblastoma tissues from N-Myc transgenic mice, and c-Myc overexpression correlated with upregulation of HDAC2 and repression of CCNG2 in tumour tissues from pancreatic cancer patients. Taken together, our data indicate the critical roles of upregulation of HDAC2 and suppression of CCNG2 in Myc-induced oncogenesis, and have significant implications for the application of HDAC inhibitors in the prevention and treatment of Myc-driven cancers.

Original languageEnglish (US)
Pages (from-to)5957-5968
Number of pages12
JournalOncogene
Volume29
Issue number44
DOIs
StatePublished - Nov 4 2010

Fingerprint

Cyclin G2
Histone Deacetylase 2
Histone Deacetylases
Up-Regulation
Neuroblastoma
Pancreatic Neoplasms
Cell Proliferation
Neoplasms
Chromatin Immunoprecipitation
Oncogene Proteins
Bromodeoxyuridine
Transgenic Mice
Genes
Carcinogenesis
Down-Regulation
Binding Sites
Gene Expression

Keywords

  • N-Myc
  • c-Myc
  • cell proliferation
  • cyclin G2
  • histone deacetylase 2

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Marshall, G. M., Gherardi, S., Xu, N., Neiron, Z., Trahair, T., Scarlett, C. J., ... Liu, T. (2010). Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene, 29(44), 5957-5968. https://doi.org/10.1038/onc.2010.332

Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. / Marshall, G. M.; Gherardi, S.; Xu, N.; Neiron, Z.; Trahair, T.; Scarlett, C. J.; Chang, D. K.; Liu, P. Y.; Jankowski, K.; Iraci, N.; Haber, M.; Norris, M. D.; Keating, J.; Sekyere, E.; Jonquieres, G.; Stossi, F.; Katzenellenbogen, Benita S; Biankin, A. V.; Perini, G.; Liu, T.

In: Oncogene, Vol. 29, No. 44, 04.11.2010, p. 5957-5968.

Research output: Contribution to journalArticle

Marshall, GM, Gherardi, S, Xu, N, Neiron, Z, Trahair, T, Scarlett, CJ, Chang, DK, Liu, PY, Jankowski, K, Iraci, N, Haber, M, Norris, MD, Keating, J, Sekyere, E, Jonquieres, G, Stossi, F, Katzenellenbogen, BS, Biankin, AV, Perini, G & Liu, T 2010, 'Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects', Oncogene, vol. 29, no. 44, pp. 5957-5968. https://doi.org/10.1038/onc.2010.332
Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ et al. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene. 2010 Nov 4;29(44):5957-5968. https://doi.org/10.1038/onc.2010.332
Marshall, G. M. ; Gherardi, S. ; Xu, N. ; Neiron, Z. ; Trahair, T. ; Scarlett, C. J. ; Chang, D. K. ; Liu, P. Y. ; Jankowski, K. ; Iraci, N. ; Haber, M. ; Norris, M. D. ; Keating, J. ; Sekyere, E. ; Jonquieres, G. ; Stossi, F. ; Katzenellenbogen, Benita S ; Biankin, A. V. ; Perini, G. ; Liu, T. / Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. In: Oncogene. 2010 ; Vol. 29, No. 44. pp. 5957-5968.
@article{5161fceb02e04ccaae060c1dc156bebf,
title = "Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects",
abstract = "Myc oncoproteins and histone deacetylases (HDACs) modulate gene transcription and enhance cancer cell proliferation, and HDAC inhibitors are among the most promising new classes of anticancer drugs. Here, we show that N-Myc and c-Myc upregulated HDAC2 gene expression in neuroblastoma and pancreatic cancer cells, respectively, which contributed to N-Myc-and c-Myc-induced cell proliferation. Cyclin G2 (CCNG2) was commonly repressed by N-Myc and HDAC2 in neuroblastoma cells and by c-Myc and HDAC2 in pancreatic cancer cells, and could be reactivated by HDAC inhibitors. 5-bromo-2′- deoxyuridine incorporation assays showed that transcriptional repression of CCNG2 was, in part, responsible for N-Myc-, c-Myc-and HDAC2-induced cell proliferation. Dual crosslinking chromatin immunoprecipitation assay demonstrated that N-Myc acted as a transrepressor by recruiting the HDAC2 protein to Sp1-binding sites at the CCNG2 gene core promoter. Moreover, HDAC2 was upregulated, and CCNG2 downregulated, in pre-cancerous and neuroblastoma tissues from N-Myc transgenic mice, and c-Myc overexpression correlated with upregulation of HDAC2 and repression of CCNG2 in tumour tissues from pancreatic cancer patients. Taken together, our data indicate the critical roles of upregulation of HDAC2 and suppression of CCNG2 in Myc-induced oncogenesis, and have significant implications for the application of HDAC inhibitors in the prevention and treatment of Myc-driven cancers.",
keywords = "N-Myc, c-Myc, cell proliferation, cyclin G2, histone deacetylase 2",
author = "Marshall, {G. M.} and S. Gherardi and N. Xu and Z. Neiron and T. Trahair and Scarlett, {C. J.} and Chang, {D. K.} and Liu, {P. Y.} and K. Jankowski and N. Iraci and M. Haber and Norris, {M. D.} and J. Keating and E. Sekyere and G. Jonquieres and F. Stossi and Katzenellenbogen, {Benita S} and Biankin, {A. V.} and G. Perini and T. Liu",
year = "2010",
month = "11",
day = "4",
doi = "10.1038/onc.2010.332",
language = "English (US)",
volume = "29",
pages = "5957--5968",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "44",

}

TY - JOUR

T1 - Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

AU - Marshall, G. M.

AU - Gherardi, S.

AU - Xu, N.

AU - Neiron, Z.

AU - Trahair, T.

AU - Scarlett, C. J.

AU - Chang, D. K.

AU - Liu, P. Y.

AU - Jankowski, K.

AU - Iraci, N.

AU - Haber, M.

AU - Norris, M. D.

AU - Keating, J.

AU - Sekyere, E.

AU - Jonquieres, G.

AU - Stossi, F.

AU - Katzenellenbogen, Benita S

AU - Biankin, A. V.

AU - Perini, G.

AU - Liu, T.

PY - 2010/11/4

Y1 - 2010/11/4

N2 - Myc oncoproteins and histone deacetylases (HDACs) modulate gene transcription and enhance cancer cell proliferation, and HDAC inhibitors are among the most promising new classes of anticancer drugs. Here, we show that N-Myc and c-Myc upregulated HDAC2 gene expression in neuroblastoma and pancreatic cancer cells, respectively, which contributed to N-Myc-and c-Myc-induced cell proliferation. Cyclin G2 (CCNG2) was commonly repressed by N-Myc and HDAC2 in neuroblastoma cells and by c-Myc and HDAC2 in pancreatic cancer cells, and could be reactivated by HDAC inhibitors. 5-bromo-2′- deoxyuridine incorporation assays showed that transcriptional repression of CCNG2 was, in part, responsible for N-Myc-, c-Myc-and HDAC2-induced cell proliferation. Dual crosslinking chromatin immunoprecipitation assay demonstrated that N-Myc acted as a transrepressor by recruiting the HDAC2 protein to Sp1-binding sites at the CCNG2 gene core promoter. Moreover, HDAC2 was upregulated, and CCNG2 downregulated, in pre-cancerous and neuroblastoma tissues from N-Myc transgenic mice, and c-Myc overexpression correlated with upregulation of HDAC2 and repression of CCNG2 in tumour tissues from pancreatic cancer patients. Taken together, our data indicate the critical roles of upregulation of HDAC2 and suppression of CCNG2 in Myc-induced oncogenesis, and have significant implications for the application of HDAC inhibitors in the prevention and treatment of Myc-driven cancers.

AB - Myc oncoproteins and histone deacetylases (HDACs) modulate gene transcription and enhance cancer cell proliferation, and HDAC inhibitors are among the most promising new classes of anticancer drugs. Here, we show that N-Myc and c-Myc upregulated HDAC2 gene expression in neuroblastoma and pancreatic cancer cells, respectively, which contributed to N-Myc-and c-Myc-induced cell proliferation. Cyclin G2 (CCNG2) was commonly repressed by N-Myc and HDAC2 in neuroblastoma cells and by c-Myc and HDAC2 in pancreatic cancer cells, and could be reactivated by HDAC inhibitors. 5-bromo-2′- deoxyuridine incorporation assays showed that transcriptional repression of CCNG2 was, in part, responsible for N-Myc-, c-Myc-and HDAC2-induced cell proliferation. Dual crosslinking chromatin immunoprecipitation assay demonstrated that N-Myc acted as a transrepressor by recruiting the HDAC2 protein to Sp1-binding sites at the CCNG2 gene core promoter. Moreover, HDAC2 was upregulated, and CCNG2 downregulated, in pre-cancerous and neuroblastoma tissues from N-Myc transgenic mice, and c-Myc overexpression correlated with upregulation of HDAC2 and repression of CCNG2 in tumour tissues from pancreatic cancer patients. Taken together, our data indicate the critical roles of upregulation of HDAC2 and suppression of CCNG2 in Myc-induced oncogenesis, and have significant implications for the application of HDAC inhibitors in the prevention and treatment of Myc-driven cancers.

KW - N-Myc

KW - c-Myc

KW - cell proliferation

KW - cyclin G2

KW - histone deacetylase 2

UR - http://www.scopus.com/inward/record.url?scp=78149468828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149468828&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.332

DO - 10.1038/onc.2010.332

M3 - Article

C2 - 20697349

AN - SCOPUS:78149468828

VL - 29

SP - 5957

EP - 5968

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 44

ER -